Clinical trials: Advanced Esophageal Cancer
Adjuvant Radiotherapy
Adjuvant Radiotherapy for Esophageal Squamous Cell Carcinoma in the Era of Immunotherapy
This study is a multicenter, prospective, randomized phase II trial aimed at exploring the value of adjuvant radiotherapy in patients at high risk of recurrence after neoadjuvant chemoradiotherapy for esophageal cancer.
- Trial name
- NCT06272214
- Testing
- Adjuvant radiotherapy, Observation
- Where
- China
- Volunteers
- 146 people
- Sponsor
- Zhejiang Cancer Hospital
Esophageal Cancer
PhaseⅠ/Ⅱ Study of URLC10-177 and TTK-567 Peptide Vaccine Combined With CpG7909 in Patients With Esophageal Cancer
This is a single institution phase I / II trial to evaluate the safety and efficacy of URLC10-177 and TTK-567 emulsified with Montanide ISA 51 in combination with different doses of CpG7909 in patients with advanced or recurrent…
- Trial name
- NCT00669292
- Testing
- URLC10-177, TTK-567, CpG-7909
- Where
- Japan
- Volunteers
- 29 people
- Sponsor
- Wakayama Medical University
Esophageal Squamous Cell Carcinoma
Neoadjuvant Adebrelimab Plus Chemotherapy for Esophageal Cancer: A Clinical Study
This is a domestic exploratory, single-arm clinical study enrolling patients with histologically or cytologically confirmed locally advanced esophageal squamous cell carcinoma (ESCC), aiming to evaluate the efficacy and safety of…
- Trial name
- NCT07437898
- Testing
- Adebrelimab, chemotherapy
- Where
- China
- Volunteers
- 42 people
- Sponsor
- The Affiliated Hospital of Putian University
Pancreatic Cancer, Small Bowel Cancer
Expanded Access to Ulixertinib (BVD-523) in Patients With Advanced MAPK Pathway-Altered Malignancies
The objective of this expanded access program is to provide ulixertinib (BVD-523) for compassionate use in advanced cancer patients with MAPK pathway-altered solid tumor(s), including but not limited to KRAS, NRAS, HRAS, BRAF…
- Conditions
- Pancreatic Cancer, Small Bowel Cancer, Colorectal Cancer, Melanoma
- Trial name
- NCT04566393
- Testing
- Ulixertinib (BVD-523)
- Where
- 26 sites in United States
- Sponsor
- xCures
Oesophageal Squamous Cell Carcinoma
A Clinical Trial of Ifinatamab Deruxtecan in People With Advanced Esophageal Cancer (MK-3475-06F)
The purpose of this trial is to assess if ifinatamab deruxtecan (I-DXd) can treat esophageal squamous cell carcinoma (ESCC). I-DXd is an antibody-drug conjugate (ADC).
- Trial name
- NCT07405151
- Testing
- I-DXd, Rescue Medication
- Where
- 32 sites in United States, Brazil and 9 more
- Volunteers
- 60 people
- Sponsor
- Merck Sharp & Dohme LLC
Gastric Cancer (GC) Gastroesophageal Junction Cancer (GEJ)
Continuation of Serplulimab Plus Chemotherapy After First Progression in Advanced Gastric or Gastro-oesophageal Junction Adenocarcinoma: an Open-label, Randomised Phase II Trial
This study is conducted in patients with advanced metastatic gastric cancer including gastroesophageal junction cancer(patients with HER2 negative and PD-L1 CPS≥5).Patiens will recevie Serplulimab plus chemotherapy…
- Trial name
- NCT05942573
- Testing
- Serplulimab+Paclitaxel+Apatinib, Paclitaxel±Ramucirumab
- Where
- China
- Volunteers
- 107 people
- Sponsor
- Tianjin Medical University Cancer Institute and Hospital
Adenocarcinomas of the Esophagogastric Junction
Sequential FDG-PET (Positron Emission Tomography) and Induction Chemotherapy in Locally Advanced Adenocarcinoma of the Esophagogastric Junction (AEG)
Prospective, single-center, nonrandomized, explorative imaging study evaluating the value of PET as a predictor of histopathological response in metabolic non-responders Patients with resectable AEG (adenocarcinoma of the…
- Trial name
- HICON (NCT01271322)
- Testing
- neoadjuvant radiochemotherapy in metabolic non responders
- Where
- Germany
- Sponsor
- National Center for Tumor Diseases, Heidelberg
Esophageal Squamous Cell Carcinoma, Neoadjuvant Therapies
Neoadjuvant Immunotherapy (PD-1 / PD-L1) Combined With Chemotherapy for Locally Advanced Thoracic Esophageal Squamous Cell Carcinoma: a Single Center, Prospective, Open, One Arm Exploratory Clinical Study
To purpose of this study is to access the safety and efficacy of neoadjuvant Immunotherapy (PD-1 / PD-L1) combined with chemotherapy for locally advanced thoracic esophageal squamous cellcarcinoma.
- Trial name
- NICCE (NCT05028231)
- Testing
- Neoadjuvant Immunotherapy (PD-1 / PD-L1) Combined With Chemotherapy
- Where
- China
- Volunteers
- 46 people, healthy volunteers welcome
- Sponsor
- Tongji Hospital
Cancer
Early Intervention vs. Standard Palliative Care in Improving End-of-Life Care in Advanced Cancer Patients
RATIONALE: Palliative care may help patients with advanced cancer live more comfortably. PURPOSE: This randomized clinical trial is studying an early intervention palliative care program to see how well it works compared to a…
- Trial name
- NCT00253383
- Testing
- counseling intervention, educational intervention, psychosocial assessment and care
- Where
- 2 sites in United States
- Volunteers
- 329 people
- Sponsor
- Dartmouth-Hitchcock Medical Center
Gastric Cancer
Trial of Panitumumab Cisplatin, Fluourouracil and Docetaxel in Locally Advanced or Metastatic Gastric Cancer
Investigators propose to study the effect of panitumumab when combined with an active regimen, such as DCF (Docetaxel/Cisplatin/Fluourouracil), in previously untreated patients with advanced cancer of the stomach.
- Trial name
- NCT01716546
- Testing
- Pazopanib
- Where
- 9 sites in Greece
- Volunteers
- 51 people
- Sponsor
- Hellenic Oncology Research Group
Esophageal Carcinoma (Squamous Cell Carcinoma - Adenocarcinoma)
Early Metabolic Response in Locally Advanced Esophageal Cancer Undergoing Induction Chemoradiotherapy
Early metabolic response evaluation may predict clinical and histopathological response after neoadjuvant chemotherapy. Its value in neoadjuvant chemoradiotherapy (CRT) is unknown.
- Trial name
- NCT01269970
- Testing
- 18-FDG-PET-CT
- Where
- Belgium
- Sponsor
- Universitaire Ziekenhuizen KU Leuven
Solid Tumors
Study of INCB123667 in Subjects With Advanced Solid Tumors
This is an open-label, dose-escalation and dose-expansion study to determine the safety, tolerability, PK, pharmacodynamics, and preliminary efficacy of INCB123667 when administered as monotherapy and in combination with…
- Trial name
- NCT05238922
- Testing
- INCB0123667, Palbociclib, Bevacizumab
- Where
- 41 sites in United States, France and 6 more
- Volunteers
- 291 people
- Sponsor
- Incyte Corporation
Esophageal Cancer
LDE225 + Everolimus in Advanced Gastroesophageal Adenocarcinoma
The goal of this clinical research study is to find the highest tolerable dose of LDE225 that can be given in combination with everolimus to patients with esophageal or GEJ cancer.
- Trial name
- NCT02138929
- Testing
- Everolimus, LDE 225
- Where
- United States
- Volunteers
- 25 people
- Sponsor
- M.D. Anderson Cancer Center
Stage III Esophageal Squamous Cell Carcinoma
A Comparison of Paclitaxel-based Three Regimens Concurrent With Radiotherapy for Patients With Local Advanced Esophageal Cancer
The purpose of this study is to determined the best scheme in paclitaxel and cisplatin，paclitaxel and fluorouracil，paclitaxel and carboplatin concurrent with radiotherapy for patients with local advanced esophageal Squamous Cell…
- Trial name
- NCT02459457
- Testing
- Paclitaxel and Cisplatin, Paclitaxel and Fluorouracil, Paclitaxel and Carboplatin
- Where
- China
- Volunteers
- 321 people
- Sponsor
- Fudan University
Esophageal Neoplasms, Esophageal Squamous Cell Carcinoma
PD-1 Inhibitor Combined With Neoadjuvant Chemotherapy in Subjects With Resectable Locally Advanced Thoracic Esophageal Squamous Cell Carcinoma
The purpose of this study is to explore the efficacy and safety of compare the efficacy and safety of PD-1 inhibitor and chemotherapy（treatment group） with chemoradiotherapy（control group） in neoadjuvant treatment of resectable…
- Trial name
- REVO (NCT05007145)
- Testing
- PD-1 inhibitor, Albumin-Bound Paclitaxel, Cisplatin
- Where
- 6 sites in China
- Volunteers
- 92 people
- Sponsor
- Fujian Cancer Hospital
Head & Neck Cancer, Pancreas Carcinoma
SL-28 for Advanced Solid Tumours
Second Life Therapeutics is developing SL-28, an allogeneic, non-genetically modified cell-based therapy for the treatment of advanced solid tumours.
- Conditions
- Head & Neck Cancer, Pancreas Carcinoma, Pancreas Cancer, Metastatic, Lung Adenocarcinoma
- Trial name
- NCT07341737
- Testing
- SL-28
- Where
- 3 sites in Australia
- Volunteers
- 60 people
- Sponsor
- Second Life Therapeutics
Non-Small Cell Lung Cancer (NSCLC), Colorectal Cancer
Study of Elironrasib and Daraxonrasib as Monotherapies and Combination Therapy in Participants With Advanced KRAS G12C Mutant Solid Tumors
This study is to evaluate the safety, tolerability, and PK profiles of Elironrasib and Daraxonrasib as monotherapies and combination therapy in patients with KRAS G12C-mutated solid tumors.
- Conditions
- Non-Small Cell Lung Cancer (NSCLC), Colorectal Cancer, Pancreatic Ductal Adenocarcinoma
- Trial name
- NCT06128551
- Testing
- Elironrasib, Daraxonrasib
- Where
- 56 sites in United States, France and 5 more
- Volunteers
- 534 people
- Sponsor
- Revolution Medicines, Inc.
Stomach Neoplasms, Esophageal Neoplasms
Study of PEP02, Irinotecan or Docetaxel in Gastric or Gastroesophageal Junction Adenocarcinoma
The purpose of this study is to assess objective tumor response in the single agent treatment of PEP02, irinotecan, or docetaxel for locally advanced or metastatic gastric or gastroesophageal junction adenocarcinoma
- Trial name
- NCT00813072
- Testing
- PEP02, irinotecan, docetaxel
- Where
- 22 sites in Bosnia and Herzegovina, Croatia and 4 more
- Volunteers
- 135 people
- Sponsor
- PharmaEngine
Solid Tumor, Advanced Cancer
Givastomig Combined With Nivolumab and Chemotherapy in Adults With CLDN18.2 Positive Metastatic Gastric Cancer (GIVA-2)
The goal of this clinical trial is to learn if givastomig in combination with standard therapy works to treat adults with cancer in the stomach and/or esophagus (GEA adenocarcinoma).
- Conditions
- Solid Tumor, Advanced Cancer, Metastatic Cancer, Gastric Cancer
- Trial name
- NCT07432295
- Testing
- Givastomig, Nivolumab, 5Fluorouracil
- Where
- 6 sites in United States, China and 1 more
- Volunteers
- 180 people
- Sponsor
- I-Mab Biopharma US Limited
Adenocarcinoma of the Gastroesophageal Junction, Esophageal Adenocarcinoma
Panitumumab, Combination Chemotherapy, & Radiation Therapy in Esophageal or Gastroesophageal Junction Cancer
This phase II trial is studying how well giving panitumumab, combination chemotherapy, and radiation therapy together before surgery works in treating patients with advanced esophageal or gastroesophageal (GE) junction cancer.
- Conditions
- Adenocarcinoma of the Gastroesophageal Junction, Esophageal Adenocarcinoma, Stage IIA Esophageal Cancer, Stage IIB Esophageal Cancer
- Trial name
- NCT01307956
- Testing
- Fluorouracil, Laboratory Biomarker Analysis, Leucovorin Calcium
- Where
- United States
- Volunteers
- 11 people
- Sponsor
- University of Nebraska